Skip links

Yargesa™ (miglustat)

Full Name Yargesa™ (miglustat)
Drug Yargesa
Manufacturer Edenbridge Pharmaceuticals
Route of Administration Oral
Site of Care Home or Healthcare Facility
Approved Indication Monotherapy for treatment of adult patients with mild/moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option
Disease Gaucher Type I Disease
Therapeutic Area Neurology, Genetics
Enrollment Form Link Yargesa Enrollment Form
Phone Number 800-240-9572
Fax Number 877-220-7581